BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

博瑞生物医药（苏州）股份有限公司

Develops and manufactures active pharmaceutical ingredients, intermediates, generics and some innovative drugs, plus R&D and manufacturing services for pharmaceutical companies, selling to over 40 countries. Ranked among top three global echinocandin API/intermediate suppliers in 2025, per CIC.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Decline in revenue or profit
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Chapter 18A biotech